Navigation Links
Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses
Date:10/19/2010

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses

http://www.reportlinker.com/p0315841/The-Top-10-Companies-in-the-Hospital-Pharmaceutical-Market-in-China-Growth-strategies-performance-and-SWOT-analyses.html

China is currently the world's second largest economy and could become the world's largest economy sometime as early as 2030. According to IMS Health data, the Chinese hospital pharmaceutical market was valued at around $26bn in 2009. Pharmaceutical companies operating in China comprise both domestic and multinational companies wherein domestic products have over 60% market share. China is one of the emerging markets most targeted by foreign players due to its increasing profitability and access to innovation. This report profiles the leading players in the Chinese hospital pharmaceutical market comprising both domestic and multinational companies. This report analyzes the hospital pharmaceutical market in China in terms of market size, key drivers and resistors, trends, and competitive positioning of major players in the market. It includes profiles of the top 10 companies in the industry and provides a brief summary of other leading players.

IntroductionThis report analyzes the hospital pharmaceutical market in China in terms of market size, key drivers and resistors, trends, and competitive positioning of major players in the market. It includes profiles of the top 10 companies in the industry and provides a brief summary of other leading players. rbhc0281

Scope of this research• Understand how recent events are affecting the performance of major companies' products.

• Gain up-to-date information across a wide range of marketed products, R&D pipelines, market share data, and competitive landscape for leading players.

• Evaluate the Chinese hospital pharmaceutical market in terms of pricing and regulation, intellectual property rights, and trends in the country.

• Compare the product franchises of top pharmaceutical players across major therapeutic areas.

• Analyze the performance of the key Chinese pharmaceutical companies.

Research and analysis highlights The hospital pharmaceutical market in China is highly competitive and fragmented, with the top 10 players accounting for 29% of the total sales in 2009. Pfizer captured the highest market share, followed by AstraZeneca and Bayer.

Owing to improving intellectual property rights (IPR), increasing medical insurance coverage of urban and rural residents and growing consumer demand for quality healthcare in China, the Chinese pharmaceutical industry is further expected to grow in the near future.

The hurdles faced by pharmaceutical companies due to the complex drug distribution system and increasing price pressures by the Chinese authorities are resistors to growth of the pharmaceutical industry.

Key reasons to purchase this research • What was the market size of the Chinese hospital pharmaceutical market in 2009 and what are the key trends in the market?

• Who were the top 10 players in the Chinese hospital pharmaceutical market in 2009 and what are their key therapeutic areas?

• What are the significant market and pipeline developments that may shape corporate strategies for leading drug majors in China?

• What is the structure of the drug regulatory system in China?

• Which are the key Traditional Chinese Medicines (TCMs) in the Chinese hospital pharmaceutical market?

Table of ContentsAbout the author 2

Disclaimer 2

Executive summary 14

Industry overview 14

Pfizer 14

AstraZeneca 15

Bayer 16

Sanofi-Aventis 16

Roche 17

Js Yangzijiang Fty 17

Merck & Co. 18

Kelun Pharmaceutical 19

Shandong Qilu 19

GlaxoSmithKline (GSK) 20

Chapter 1 Scope and methodology 21

Scope 21

Methodology 21

IMS caveat 22

Chapter 2 Industry overview 23

Summary 23

Introduction 23

Key market drivers and resistors 24

Market drivers 24

Market resistors 25

The Chinese healthcare system 26

Chinese drug approval system 28

Chinese drug regulatory system 29

Intellectual property protection 31

Pricing and reimbursement 33

Drug distribution system 35

Recent healthcare reforms and their impact on the Chinese pharmaceutical industry 37

Generics market in China 39

Biotech developments in China 41

Improving scientific base 43

Chinese biosimilar market 43

Major biosimilars in China 45

Traditional Chinese medicines (TCMs) 46

Market dynamics 47

Chinese pharmaceutical market size and growth 47

Leading therapeutic areas 48

Competitive landscape 49

Competitive positioning of the top 10 companies 49

Chapter 3 Pfizer 52

Summary 52

Company overview 53

Therapeutic area focus 54

Marketed product portfolio 55

Research and development 56

Growth strategies 58

Co-promotion of Takeda's Actos 58

Strategic partnership with BMP Sunstone to co-promote Depo-Provera 58

Pfizer's recent developments in the R&D sector 58

SWOT analysis 60

Chapter 4 AstraZeneca 61

Summary 61

Company overview 62

Therapeutic area focus 62

Marketed product portfolio 63

Research and development 64

Growth strategies 65

Establishment of API production, medicine formulation and packaging sites in China 65

R&D investments in China 66

AstraZeneca's new site in Zhangjiang, High-Tech Park 66

SWOT analysis 67

Chapter 5 Bayer 68

Summary 68

Company overview 69

Therapeutic area focus 69

Marketed product portfolio 70

Research and development 71

Growth strategies 72

Establishment of Bayer-Tsinghua Research Center 72

Partnership with the People's Liberation Army General Hospital 72

Strategic acquisitions and in-licensing of products in China 73

SWOT analysis 74

Chapter 6 Sanofi-Aventis 75

Summary 75

Company overview 76

Therapeutic area focus 76

Marketed product portfolio 77

Research and development 79

Growth strategies 81

Sanofi-Aventis's alliances and partnerships in China 81

Increasing R&D and expanding manufacturing capabilities in China 81

SWOT analysis 82

Chapter 7 Roche 83

Summary 83

Company overview 83

Therapeutic area focus 84

Marketed product portfolio 85

Research and development 86

Growth strategies 88

Extensive R&D activity at its center in Shanghai 88

Establishment of manufacturing units in China 88

SWOT analysis 89

Chapter 8 Js.Yangzijiang Fty 90

Summary 90

Company overview 91

Therapeutic area focus 91

Marketed product portfolio 92

Research and development 92

SWOT analysis 93

Chapter 9 Merck & Co. 94

Summary 94

Company overview 95

Therapeutic area focus 95

Marketed product portfolio 96

Research and development 97

Growth strategies 98

Joint venture with Sinopharm to market human papillomavirus vaccines (HPV) 98

Establishment of Merck Serono's R&D center in China 99

SWOT analysis 99

Chapter 10 Kelun group 100

Summary 100

Company overview 101

Therapeutic area focus 101

Marketed product portfolio 102

Research and development 103

SWOT analysis 104

Chapter 11 Shandong Qilu Fty 105

Summary 105

Company overview 106

Therapeutic area focus 106

Marketed product portfolio 107

Research and development 108

SWOT analysis 109

Chapter 12 GlaxoSmithKline (GSK) 110

Summary 110

Company overview 111

Therapeutic area focus 112

Marketed product portfolio 113

Research and development 114

Growth strategies 115

Joint venture with Shenzhen Neptunus to develop influenza vaccines 115

Joint venture with Jiangsu Walvax to develop pediatric vaccines 115

China to be GSK's center for global R&D in the near future 116

Drapolene launched in China 116

SWOT analysis 117

Chapter 13 11- 15 companies 118

Novartis 118

Company overview 118

Therapeutic area focus 118

Marketed products 120

Research and development 120

Js.L.Y.G. Hengrui 121

Company overview 121

Therapeutic area focus 121

Marketed products 123

Research and development 123

Hlj.Haerbin Pharmaceuticals 124

Company overview 124

Therapeutic focus 124

Marketed products 126

Research and development 126

Fresenius 127

Company overview 127

Therapeutic focus 127

Marketed products 129

Research and development 130

Novo Nordisk 130

Company overview 130

Therapeutic focus 130

Marketed products 131

Research and development 132

Appendix 133

Anatomical therapeutic chemical (ATC) classification 133

A: Alimentary tract and metabolism 133

B: Blood and blood-forming organs 133

C: Cardiovascular system 133

D: Dermatologicals 133

G: Genitourinary system and sex hormones 133

H: Systemic hormonal preparations 133

J: General anti-infectives systemic 134

K: Hospital solutions 134

L: Antineoplastic and immunomodulating agents 134

M: Musculo-skeletal system 134

N: Nervous system 134

P: Parasitology 134

R: Respiratory system 134

S: Sensory organs 135

T: Diagnostic agents 135

V: Various 135

Glossary 136

Table of figuresFigure 1: Key market drivers and resistors of Chinese pharmaceutical market 26

Figure 2: Drug approval process followed by the SFDA 28

Figure 3: Changes to the patent regime which will affect life science companies 33

Figure 4: Five-step procedure for drug pricing followed by NDRC 34

Figure 5: Drug distribution channels in China 36

Figure 6: Change in the pharmaceutical industry sector due to healthcare reforms and their

impact on key industry players 39

Figure 7: Market positioning of the top 10 companies in China, 2009 51

Figure 8: Pfizer's Chinese market sales by therapy area, 2009 55

Figure 9: Pfizer China's SWOT analysis 60

Figure 10: AstraZeneca's Chinese market sales by therapy area, 2009 63

Figure 11: AstraZeneca China's SWOT analysis 67

Figure 12: Bayer's Chinese market sales by therapy area, 2009 70

Figure 13: Bayer China's SWOT analysis 74

Figure 14: Sanofi-Aventis's Chinese market sales by therapy area, 2009 77

Figure 15: Sanofi-Aventis China's SWOT analysis 82

Figure 16: Roche's Chinese market sales by therapy area, 2009 85

Figure 17: Shanghai Roche's SWOT analysis 89

Figure 18: Js Yangzijiang Fty 's Chinese market sales by therapy area, 2009 91

Figure 19: Js Yangzijiang's SWOT analysis 93

Figure 20: Merck & Co's Chinese market sales by therapy area, 2009 96

Figure 21: Merck China's SWOT analysis 99

Figure 22: Kelun pharmaceutical's Chinese market sales by therapy area, 2009 102

Figure 23: Kelun's SWOT analysis 104

Figure 24: Shandong Qilu's Chinese market sales by therapy area, 2009 107

Figure 25: Shandong Qilu's SWOT analysis 109

Figure 26: GSK's Chinese market sales by therapy area, 2009 113

Figure 27: GSK China's SWOT analysis 117

Figure 28: Novartis's Chinese market sales by therapy area, 2009 119

Figure 29: Js.L.Y.G. Hengrui's Chinese market sales by therapy area, 2009 122

Figure 30: Hlj.Haerbin's Chinese market sales by therapy area, 2009 125

Figure 31: Fresenius' Chinese market sales by therapy area, 2009 128

Figure 32: Novo Nordisk's Chinese market sales by therapy area, 2009 131

Table of TablesTable 1: Chinese hospital pharmaceutical market size and growth, 2009 47

Table 2: Forecast Chinese hospital pharmaceutical market size, 2009-15 48

Table 3: Chinese hospital pharmaceutical market by therapeutic segmentation, 2009 49

Table 4: Top 10 companies in Chinese hospital pharmaceutical market ($m), 2009 50

Table 5: Pfizer China Snapshot 53

Table 6: Pfizer's top 10 marketed products by sales ($m), 2009 56

Table 7: Pfizer's late-stage R&D pipeline, 2010 57

Table 8: AstraZeneca China snapshot 61

Table 9: AstraZeneca's top 10 marketed products by sales ($m), 2009 64

Table 10: AstraZeneca's late- stage R&D pipeline, 2010 (Phase III trials ongoing in China) 65

Table 11: Bayer China Snapshot 68

Table 12: Bayer's top 10 marketed products by sales ($m), 2009 71

Table 13: Bayer's late-stage R&D pipeline, 2010 72

Table 14: Sanofi-Aventis China snapshot 76

Table 15: Sanofi-Aventis's top 10 marketed products by sales ($m), 2009 78

Table 16: Sanofi-Aventis's late-stage R&D pipeline, 2010 80

Table 17: Shanghai Roche's snapshot 83

Table 18: Roche's top 10 marketed products by sales ($m), 2009 86

Table 19: Roche's late-stage R&D pipeline, 2010 87

Table 20: Js Yangzijiang Fty snapshot 90

Table 21: Js Yangzijiang's top 10 marketed products by sales ($m), 2009 92

Table 22: Merck & Co China snapshot 94

Table 23: Merck's top 10 marketed products by sales ($m), 2009 97

Table 24: Merck & Co's late-stage R&D pipeline, 2010 98

Table 25: Kelun Pharmaceutical snapshot 100

Table 26: Kelun's top 10 marketed products by sales ($m), 2009 103

Table 27: Shandong Qilu Fty snapshot 105

Table 28: Shandong Qilu's top 10 marketed products by sales ($m), 2009 108

Table 29: GSK China snapshot 111

Table 30: GSK's top 10 marketed products by sales ($m), 2009 114

Table 31: GSK China's late-stage R&D pipeline, 2010 115

Table 32: Novartis (China) snapshot 118

Table 33: Novartis's top 10 marketed products by sales ($m), 2009 120

13

Table 34: Js.L.Y.G. Hengrui snapshot 121

Table 35: Js.L.Y.G. Hengrui's top 10 marketed products by sales ($m), 2009 123

Table 36: Hlj.Haerbin Pharmaceuticals snapshot 124

Table 37: Hlj.Haerbin's top 10 marketed products by sales ($m), 2009 126

Table 38: Fresenius China snapshot 127

Table 39: Fresenius's top 10 marketed products by sales ($m), 2009 129

Table 40: Novo Nordisk China snapshot 130

Table 41: Novo Nordisk's top 10 marketed products by sales ($m), 2009 132

To order this report:Medical Facility Industry: The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses

Medical Facility Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact Nicolas BombourgReportlinkerEmail: nbo@reportlinker.com US: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Lung Cancer Drug Futures
2. Reportlinker Adds Prostate Cancer Drug Futures
3. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
4. Reportlinker Adds Deep Analysis Report on Chinas Disinfectant Market 2010-2015
5. Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures
6. Reportlinker Adds The Top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends
7. Reportlinker Adds Global Minimally Invasive Surgery Market.(2010 - 2015)
8. Reportlinker Adds Global Diagnostic ECG Market (2010 - 2015)
9. Reportlinker Adds Global Wound Care Products Industry
10. Reportlinker Adds Global Veterinary Vaccines Industry
11. Reportlinker Adds Global Urological Catheters Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb.8, 2016 Respiratory Devices - Medical ... Medical Devices sector report, " Respiratory Devices - ... overview of Respiratory Devices currently in pipeline stage. ... pipeline products with comparative analysis of the products ... major players involved in the pipeline product development. ...
(Date:2/8/2016)... CBG Technologies, a U.S. company, is ... Systems, specifically designed for precision parts cleaning. The ... existing vapor degreasers, parts washers and ultrasonic cleaning ... recycling and recovers 100% of the solvent for ... Precision parts manufacturers benefit from this progressive ...
(Date:2/8/2016)... , Feb. 8, 2016  Echo Therapeutics, ... device company focused on non-invasive continuous glucose ... today announced that it will host a ... 17, 2015 at 9:00 a.m. Eastern Time ... its corporate strategy, advancements in its CGM ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):